Telomir Pharmaceuticals

Telomir Pharmaceuticals is a Tampa, Florida-based pre-clinical-stage pharmaceutical company developing small-molecule interventions targeting metal-driven aging, cellular senescence, and age-related disease. The lead investigational compound Telomir-1 is being studied for metal-ion homeostasis modulation, with research-stage indications in age-related metabolic disease and oncology-supportive care. Founded by Dr. Christopher Chapman, the company trades on Nasdaq under the symbol TELO and operates as a pre-revenue clinical-development entity. As of mid-2026 Telomir has been positioning Telomir-1 toward first-in-human studies while running IND-enabling toxicology and pharmacokinetic work in parallel.